
Darren Keith McGuire MD
Distinguished Teaching Professor, Internal Medicine, Dallas Heart Ball Chair for Heart Disease Research in Women, University of Texas Southwestern Medical Center, Deputy Editor, Circulation
Join to View Full Profile
5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-645-8000
Fax+1 214-645-7269
Dr. McGuire is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Duke University HospitalFellowship, Cardiovascular Disease, 1997 - 2001
- Duke University School of MedicineM.H.S., Clinical Research Training Program, 1998 - 2000
- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1993 - 1996
- Johns Hopkins University School of MedicineClass of 1993
- Hendrix CollegeB.A., Chemistry, Summa Cum Laude, 1985 - 1989
Certifications & Licensure
- TX State Medical License 1994 - 2026
- NC State Medical License 1996 - 2002
- VA State Medical License 1999 - 2000
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Fellow (FESC) European Society of Cardiology
- Fellow (FAHA) AHA
- Regents Outstanding Teacher Award University of Texas Board of Regents, 2013
- Join now to see all
Clinical Trials
- Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride Start of enrollment: 2005 Feb 01
Publications & Presentations
PubMed
- 2 citationsTreatment strategies to reduce cardiovascular risk in persons with chronic kidney disease and Type 2 diabetes.Faiez Zannad, Darren K McGuire, Alberto Ortiz
Journal of Internal Medicine. 2025-05-01 - Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A ...Matthew M Y Lee, Naveed Sattar, Rodica Pop-Busui, John Deanfield, Scott S Emerson
Diabetes Care. 2025-05-01 - Novel therapeutic agents for cardiometabolic risk mitigation in heart transplant recipients.Ananya Gorrai, Maryjane Farr, Patrick O'hara, Hadi Beaini, Nicholas Hendren
The Journal of Heart and Lung Transplantation. 2025-04-01
Journal Articles
- Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults with DiabetesMichael C Honigberg, Ravi B Patel, Javed Butler, Darren K Mcguire, JAMA Cardiology
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart FailureDeepak L Bhatt, Darren K Mcguire, Jeffrey M Testani, Pablo Lapuerta, Bertram Pitt, The New England Journal of Medicine
- Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 DiabetesDarren K Mcguire, Samuel Dagogo-Jack, Urszula Masiukiewicz, JAMA Cardiology
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- A1C : Glucose management in type 2 diabetes mellitus.Goyal A, Kosiborod M, McGuire DK, Garber AJ, American College of Cardiology Foundation Diabetes Self-Assessment Program, Washington, DC, 1/1/2011
Lectures
- Assessment of Omega‐3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale a...Scientific Sessions 2008, New Orleans, Louisiana, USA
- Assessment of Omega‐3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale a...Scientific Sessions 2007, Orlando, Florida, USA
- Assessment of Omega‐3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale a...International Chair on Cardiometabolic Risk, 2nd International Congress on Abdominal Obesity, Buenos
- Join now to see all
Other
- The TECOS Trial of Sitagliptin vs. Placebo: Context and Cardiovascular Observations.Gore MO, McGuire DK
http://www.acc.org/latest-in-cardiology/articles/2015/11/20/14/19/the-tecos-trial-of-sitagliptin-vs-placebo
1/23/2015 - MY APPROACH to Sulfonylureas in Patients With Coronary Artery Disease.McGuire DK, Gore O, PracticeUpdate
http://www.practiceupdate.com/ExpertOpinion/1088/1/8
1/10/2014 - Consultant Live Podcast: DPP 4 InhibitorsMcGuire DK
http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2129971
1/27/2013 - Join now to see all
Authored Content
- Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes and Cardiovascular DiseaseJune 2020
- Heart Failure Epidemiology in Patients with Diabetes Mellitus Without Coronary Heart DiseaseNovember 2018
- Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients with Type 2 DiabetesMarch 2018
Press Mentions
- Oral Semaglutide Yields Excellent CV Outcomes in High-Risk Type 2 DiabetesMay 1st, 2025
- Novo Nordisk A/S: Rybelsus® (Oral Semaglutide 14 Mg) Demonstrates Superior Reduction in Cardiovascular Events in the SOUL Trial at ACC 2025March 31st, 2025
- Oral Semaglutide Reduces Heart Risks While Helping Patients Move Past ‘Fear of the Needle’March 30th, 2025
- Join now to see all
Grant Support
- Rosiglitazone VS Placebo: Effect Of CV Performance And Myocardial TriglycerideNational Center For Research Resources2005–2007
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: